Status:
COMPLETED
Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Osteoporosis Postmenopausal
Eligibility:
All Genders
45-85 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the dose-response on the percent change from baseline in lumbar spine bone mineral density (BMD) at lumbar vertebrae 1 to 4 (L1- L4) when odanacatib (MK-0822) 10...
Eligibility Criteria
Inclusion
- Postmenopausal woman (for at least 5 years) or men who are aged between 45 to 85
- Participant who has low bone mineral density
- Participant has anatomy suitable for dual-energy x-ray absorptiometry (DXA) of the lumber spine and hip
- Participant is ambulatory (can walk)
Exclusion
- Participant has secondary osteoporosis or has a metabolic bone disorder other than osteoporosis or osteopenia
- Participant has received osteoporosis medications or other medications that affect bone
- Participant is already participating in another drug study
Key Trial Info
Start Date :
December 3 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 29 2009
Estimated Enrollment :
287 Patients enrolled
Trial Details
Trial ID
NCT00620113
Start Date
December 3 2007
End Date
May 29 2009
Last Update
August 27 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.